• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    11/12/24 9:51:26 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ASND alert in real time by email
    SC 13G/A 1 d897450dsc13ga.htm SC 13G/A SC 13G/A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    WASHINGTON, D.C. 20549

     

     

    SCHEDULE 13G

    (Rule 13d-102)

    Information to be Included in Statements Filed Pursuant to Rule 13d-1(b), (c)

    and (d) and Amendments Thereto Filed Pursuant to Rule 13d-2.

    Under the Securities Exchange Act of 1934

    (Amendment No. 5 )*

     

     

    Ascendis Pharma A/S

    (Name of Issuer)

    American Depositary Shares

    (Title of Class of Securities)

    04351P101

    (CUSIP Number)

    9/30/2024

    (Date of Event Which Requires Filing of this Statement)

     

     

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:

     

      ☒

    Rule 13d-1(b)

     

      ☐

    Rule 13d-1(c)

     

      ☐

    Rule 13d-1(d)

     

    *

    The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).

     

     

     


    CUSIP No. 04351P101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Limited Partnership

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5   

     SOLE VOTING POWER

     

     None

       6  

     SHARED VOTING POWER

     

     3,771,469

       7  

     SOLE DISPOSITIVE POWER

     

     None

       8  

     SHARED DISPOSITIVE POWER

     

     4,411,111

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,411,111

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions) ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     7.3%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     IA


    CUSIP No. 04351P101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Investments GP LLC

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     3,771,469

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     4,411,111

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,411,111

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions) ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     7.3%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC

     


    CUSIP No. 04351P101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Holdings LP

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     3,771,469

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     4,411,111

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,411,111

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions) ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     7.3%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC

     


    CUSIP No. 04351P101    13G   

     

     1   

     NAME OF REPORTING PERSON

     

     Artisan Partners Asset Management Inc.

     2  

     CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP (see Instructions)

     (a) ☐  (b) ☐

     

     Not Applicable

     3  

     SEC USE ONLY

     

     4  

     CITIZENSHIP OR PLACE OF ORGANIZATION

     

     Delaware

    NUMBER OF

    SHARES  BENEFICIALLY 

    OWNED BY

    EACH

    REPORTING

    PERSON

    WITH

       5    

     SOLE VOTING POWER

     

     None

       6   

     SHARED VOTING POWER

     

     3,771,469

       7   

     SOLE DISPOSITIVE POWER

     

     None

       8   

     SHARED DISPOSITIVE POWER

     

     4,411,111

     9   

     AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON

     

     4,411,111

    10  

     CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (see Instructions) ☐

     

     Not Applicable

    11  

     PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)

     

     7.3%

    12  

     TYPE OF REPORTING PERSON (see Instructions)

     

     HC

     


    Item 1(a)

    Name of Issuer:

    Ascendis Pharma A/S

     

    Item 1(b)

    Address of Issuer’s Principal Executive Offices:

    Tuborg Boulevard 12, DK-2900 Hellerup, Denmark

     

    Item 2(a)

    Name of Person Filing:

    Artisan Partners Limited Partnership (“APLP”)

    Artisan Investments GP LLC (“Artisan Investments”)

    Artisan Partners Holdings LP (“Artisan Holdings”)

    Artisan Partners Asset Management Inc. (“APAM”)

     

    Item 2(b)

    Address of Principal Business Office:

    APLP, Artisan Investments, Artisan Holdings, and APAM are all located at:

    875 East Wisconsin Avenue, Suite 800

    Milwaukee, WI 53202

     

    Item 2(c)

    Citizenship:

    APLP is a Delaware limited partnership

    Artisan Investments is a Delaware limited liability company

    Artisan Holdings is a Delaware limited partnership

    APAM is a Delaware corporation

     

    Item 2(d)

    Title of Class of Securities:

    American Depositary Shares

     

    Item 2(e)

    CUSIP Number:

    04351P101

     

    Item 3

    Type of Person:

    (e) APLP is an investment adviser registered under section 203 of the Investment Advisers Act of 1940.

    (g) Artisan Holdings is the sole limited partner of APLP and the sole member of Artisan Investments; Artisan Investments is the general partner of APLP; APAM is the general partner of Artisan Holdings.


    Item 4

    Ownership (at 9/30/2024):

     

      (a)

    Amount owned “beneficially” within the meaning of rule 13d-3:

    4,411,111

     

      (b)

    Percent of class:

    7.3% (based on 60,642,144 shares outstanding as of 9/27/2024)

     

      (c)

    Number of shares as to which such person has:

     

      (i)

    sole power to vote or to direct the vote: None

      (ii)

    shared power to vote or to direct the vote: 3,771,469

      (iii)

    sole power to dispose or to direct the disposition of: None

      (iv)

    shared power to dispose or to direct the disposition of: 4,411,111

     

    Item 5

    Ownership of Five Percent or Less of a Class:

    Not Applicable

     

    Item 6

    Ownership of More than Five Percent on Behalf of Another Person:

    The shares reported herein have been acquired on behalf of discretionary clients of APLP. Persons other than APLP are entitled to receive all dividends from, and proceeds from the sale of, those shares. None of those persons, to the knowledge of APLP, Artisan Holdings, APAM, or Artisan Investments has an economic interest in more than 5% of the class.

     

    Item 7

    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person:

    Not Applicable

     

    Item 8

    Identification and Classification of Members of the Group:

    Not Applicable

     

    Item 9

    Notice of Dissolution of Group:

    Not Applicable

     

    Item 10

    Certification:

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect.


    Signature

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

    Date: 11/12/2024

     

    ARTISAN PARTNERS ASSET MANAGEMENT INC,

    for itself and as the general partner of

    ARTISAN PARTNERS HOLDINGS LP
    By:   Gregory K. Ramirez *

    ARTISAN INVESTMENTS GP LLC,

    for itself and as the general partner of

    ARTISAN PARTNERS LIMITED PARTNERSHIP
    By:   Gregory K. Ramirez *
    *By:   /s/ Gregory K. Ramirez
      Gregory K. Ramirez
      Executive Vice President of Artisan Partners Asset Management Inc.
      Vice President of Artisan Investments GP LLC


    Exhibit Index

     

    Exhibit 1    Joint Filing Agreement dated 11/12/2024 by and among Artisan Partners Limited Partnership, Artisan Investments GP LLC, Artisan Partners Holdings LP, and Artisan Partners Asset Management Inc.
    Get the next $ASND alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASND

    DatePrice TargetRatingAnalyst
    5/19/2026$355.00Buy
    Citigroup
    3/16/2026Buy
    Jefferies
    1/28/2026$342.00Overweight
    Barclays
    11/18/2025$255.00Peer Perform
    Wolfe Research
    10/17/2025$271.00Strong Buy
    Raymond James
    7/3/2025$250.00Overweight
    Morgan Stanley
    5/5/2025$250.00Equal-Weight → Overweight
    Morgan Stanley
    4/16/2025$205.00Outperform
    RBC Capital Mkts
    More analyst ratings

    $ASND
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)

    4 - Ascendis Pharma A/S (0001612042) (Issuer)

    6/2/26 4:25:15 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)

    4 - Ascendis Pharma A/S (0001612042) (Issuer)

    6/1/26 4:11:13 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)

    4 - Ascendis Pharma A/S (0001612042) (Issuer)

    6/1/26 4:10:28 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    EVP & Chief Financial Officer Smith Scott Thomas bought $21,900 worth of Ordinary Shares (100 units at $219.00), increasing direct ownership by 2% to 4,367 units (SEC Form 4)

    4 - Ascendis Pharma A/S (0001612042) (Issuer)

    6/2/26 4:25:15 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Director Bienaime Jean Jacques bought $111,562 worth of Ordinary Shares (500 units at $223.12), increasing direct ownership by 125% to 900 units (SEC Form 4)

    4 - Ascendis Pharma A/S (0001612042) (Issuer)

    6/1/26 4:11:13 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    EVP & Chief Financial Officer Smith Scott Thomas bought $55,830 worth of Ordinary Shares (250 units at $223.32), increasing direct ownership by 6% to 4,267 units (SEC Form 4)

    4 - Ascendis Pharma A/S (0001612042) (Issuer)

    6/1/26 4:10:28 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Children with Achondroplasia Treated with TransCon CNP Showed Continued Improvements in Lower Extremity Alignment at Week 104 of the Pivotal ApproaCH Trial

    Data presented during ICCBH 2026 showed that improvements in tibial-femoral angle (TFA), a measure of lower extremity alignment, continued through Week 104Greater improvements observed in children with preexisting genu varum (leg bowing) COPENHAGEN, Denmark, June 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced new radiographic data from Week 104 from the completed pivotal ApproaCH Trial of once-weekly TransCon CNP (navepegritide) in children with achondroplasia. In the trial, TransCon CNP-treated children demonstrated continued improvements in lower extremity alignment through up to two years of treatment, including improvements in tibial-femoral angle (TFA)

    6/30/26 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis Joins Multiple Russell U.S. Indexes, Including the Russell 3000®, Russell 1000®, Russell 2500® and Russell Midcap®

    COPENHAGEN, Denmark, June 26, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the Company has been added to the broad-market Russell 3000® Index, the large-cap Russell 1000® Index, the small-to-mid-cap Russell 2500® Index, and the Russell Midcap® Index as a part of the 2026 Russell U.S. Indexes semi-annual reconstitution, effective at the close of U.S. equity markets on June 26, 2026. The Russell 3000® Index tracks the largest 3,000 U.S. stocks, representing approximately 98% of investable U.S. equities by market capitalization. Within the Russell 3000®, the Russell 1000® Index comprises the 1,000 largest securities, representing more than 90% of investable

    6/26/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis to Showcase Advances in Treatment of Achondroplasia at ICCBH 2026

    COPENHAGEN, Denmark, June 25, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the latest data from its clinical development programs for the treatment of children with achondroplasia will be shared in an oral presentation and two posters at ICCBH 2026, the 12th International Conference on Children's Bone Health being held in Montreal from June 27-30. The data include an oral presentation of Week 104 data showing improvements in lower-extremity alignment from the recently completed pivotal ApproaCH Trial of TransCon® CNP (navepegritide) by Leanne Ward, M.D., Professor of Pediatrics in the Faculty of Medicine at the University of Ottawa (Canada), as well as a

    6/25/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    SEC Filings

    View All

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    7/15/26 4:57:08 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    6/30/26 4:05:27 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Ascendis Pharma A/S

    6-K - Ascendis Pharma A/S (0001612042) (Filer)

    6/29/26 4:05:13 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Citigroup initiated coverage on Ascendis Pharma with a new price target

    Citigroup initiated coverage of Ascendis Pharma with a rating of Buy and set a new price target of $355.00

    5/19/26 8:29:23 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies resumed coverage on Ascendis Pharma

    Jefferies resumed coverage of Ascendis Pharma with a rating of Buy

    3/16/26 9:36:08 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Ascendis Pharma with a new price target

    Barclays initiated coverage of Ascendis Pharma with a rating of Overweight and set a new price target of $342.00

    1/28/26 7:15:39 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Leadership Updates

    Live Leadership Updates

    View All

    Ascendant Resources Announces Results of Annual General Meeting of Shareholders

    TORONTO, ON / ACCESSWIRE / June 13, 2024 / Ascendant Resources Inc. (TSX:ASND)(OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting resultsof the Company's 2024 Annual General Shareholders' Meeting (the "Meeting") held on June 13, 2024, in Toronto, Ontario.A total of 51,497,589 common shares were voted at the Meeting, representing 27.59% of the votes attached to all outstanding common shares of the Company. All matterspresented for shareholder approval at the Meeting were duly authorized and approved as follows:Number of Directors to be ElectedOn a vote by a show of hands, the resolution to set the number of directors to be elected at the meeting at six (6) was approv

    6/13/24 5:55:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New Company Eyconis Formed to Develop Ascendis Pharma Ophthalmology Assets with $150 Million Commitment from External Investors

    COPENHAGEN, Denmark, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced the formation and launch with Frazier Life Sciences of Eyconis, Inc., a separate company created to develop, manufacture, and commercialize TransCon ophthalmology assets globally, together with an investor syndicate that includes Frazier, RA Capital Management, venBio, and HealthQuest Capital. Ascendis Pharma has granted Eyconis exclusive rights to develop and commercialize TransCon ophthalmology products globally and received an equity position in the newly formed company. In addition, Ascendis will be eligible to receive development, regulatory, and sales milestone payments of up to

    1/29/24 8:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendant Resources Announces Results of Annual and Special Meeting of Shareholders

    TSX: ASNDwww.ascendantresources.com All matters overwhelmingly approved by shareholdersTORONTO, Aug. 23, 2023 /PRNewswire/ - Ascendant Resources Inc. (TSX:ASND) (OTCQB:ASND) ("Ascendant" or the "Company") is pleased to announce the voting results of the Company's 2023 Annual and Special Shareholders' Meeting (the "Meeting") held on August 23, 2023, in Toronto, Ontario. A total of 43,635,681 common shares were voted at the Meeting, representing 32.98% of the votes attached to all outstanding common shares of the Company.  All matters presented for shareholder approval at the Me

    8/23/23 4:48:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Financials

    Live finance-specific insights

    View All

    Ascendis Pharma Reports First Quarter 2026 Financial Results

    - Q1 2026 revenue of €197 million for YORVIPATH® and €44 million for SKYTROFA® - More than 1,000 new patient enrollments for YORVIPATH in the U.S. in Q1 - As of May 1, more than 60 YUVIWEL® enrollments since early April U.S. commercial launch - Entered into agreement to sell Rare Pediatric Disease Priority Review Voucher for $187.5 million - Conference call today at 8:00 am ET COPENHAGEN, Denmark, May 07, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced financial results for the first quarter ended March 31, 2026, and provided a business update. "The FDA approval of YUVIWEL, our third consecutive TransCon product, and the robust patient uptake for YORVIPATH

    5/7/26 7:30:00 AM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Ascendis to Report First Quarter 2026 Financial Results and Provide Business Update on May 7, 2026

    COPENHAGEN, Denmark, April 30, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced it plans to report first quarter 2026 financial results and provide a business update on Thursday, May 7, 2026, before the open of the U.S. financial markets. Ascendis Pharma also plans to host a conference call and live webcast on May 7, 2026, at 8:00 a.m. Eastern Time (ET) to discuss its first quarter 2026 financial results. Those who would like to participate may access the live webcast here, or register in advance for the teleconference here. The link to the live webcast will also be available on the Investors & News section of the Ascendis Pharma website at https://investors.asce

    4/30/26 4:01:00 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    FDA Approves Once-Weekly YUVIWEL® (navepegritide) for Children with Achondroplasia Aged 2 Years and Older

    The first and only approved achondroplasia therapy to provide continuous systemic exposure to CNP over the weekly dosing intervalCommercial availability expected during early part of Q2 2026Rare Pediatric Disease Priority Review Voucher granted in connection with approvalAscendis to host investor conference call Monday, March 2, at 8:00 am ET COPENHAGEN, Denmark, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Ascendis Pharma A/S (NASDAQ:ASND) today announced that the U.S. Food & Drug Administration (FDA) has granted approval under the FDA's Accelerated Approval Program for YUVIWEL® (navepegritide; developed as TransCon® CNP), the first and only once-weekly treatment indicated to increase linear growt

    2/27/26 5:57:16 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASND
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 5:46:12 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 2:57:14 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Ascendis Pharma A/S

    SC 13G/A - Ascendis Pharma A/S (0001612042) (Subject)

    11/14/24 1:28:32 PM ET
    $ASND
    Biotechnology: Pharmaceutical Preparations
    Health Care